|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 Chronic noncommunicable diseases in migrants from the area of the antiterrorist operation: is it a medical or social problem?G.D. Fadieienko, G.S. Isaeva, M.M. Vovchenko, T.G. StarchenkoSI «National Institute of Therapy named after L.T. Mala of the NAMS of Ukraine», Kharkiv |
---|
Keywords: chronic noncommunicable diseases, risk factors, migration.
List of references:
1. Ministry of social policy of Ukraine URL: http://www.msp.gov.ua/news/12682.html
2. Agyemang C, Nyaaba G, Beune E, et al. Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana - the RODAM study. J Hypertens. 2017. doi: 10.1097/HJH.00000 00000001520.
3. Andersen GS, Kamper-Jrgensen Z, Carstensen B, et al. Diabetes among migrants in Denmark: Incidence, mortality, and prevalence based on a longitudinal register study of the entire Danish population. Diabetes. Res. Clin. Pract. 2016;122:9-16. doi: 10.1016/j.diabres.2016.09.020.
4. Balaam MC, Akerjordet K, Lyberg A, et al. A qualitative review of migrant women’s perceptions of their needs and experiences related to pregnancy and childbirth. J Adv Nurs. 2013;69 (9):1919-1930. doi: 10.1111/jan.12139.
5. Bhargava S, Tsuruda K, Moen K, et al. Lower attendance rates in immigrant versus non-immigrant women in the Norwegian Breast Cancer Screening Programme. J Med Screen. 2017;1:969141317733771. doi: 10.1177/09691413 17733771.
6. Bi Y, Wang L, Xu Y, et al. China Noncommunicable Disease and Risk Factor Surveillance in Migrant Workers Study Group. Diabetes-related metabolic risk factors in internal migrant workers in China: a national surveillance study. Lancet Diabetes Endocrinol. 2016;4 (2):125-135. doi: 10.1016/ S 2213-8587(15)00366-6.
7. Bronzato S, Durante A. A Contemporary Review of the Relationship between Red Meat Consumption and Cardiovascular Risk. Int J Prev Med. 2017;8:40. doi: 10.4103/ijpvm.IJPVM_206_16.
8. Bustamante LHU, Cerqueira RO, Leclerc E, Brietzke E. Stress, trauma, and posttraumatic stress disorder in migrants: a comprehensive review. Rev Bras Psiquiatr. 2017. doi: 10.1590/1516-4446-2017-2290.
9. Chan K, Tse T, Tam D, Huang A. Perception of healthy and unhealthy food among Chinese adolescents. Young Consumers. 2015;1(17):32-45.
10. Chen W, Hall BJ, Ling L, Renzaho AM. Pre-migration and post-migration factors associated with mental health in humanitarian migrants in Australia and the moderation effect of post-migration stressors: findings from the first wave data of the BNLA cohort study. Lancet Psychiatry. 2017;4 (3):218-229. doi: 10.1016/S 2215-0366(17)30032-9.
11. Cimas M, Gullon P, Aguilera E, et al. Healthcare coverage for undocumented migrants in Spain: Regional differences after Royal Decree Law 16/2012. Health Policy. 2016;120 (4):384-395. doi: 10.1016/j.healthpol.2016.02.005.
12. Curti ML, Jacob P, Borges M.C. et al. Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J. Obes. 2011;2011. Ð. 497401. doi: 10.1155/2011/497401.
13. Darlington-Pollock F, Shackleton N, Norman P, et al. Differences in the risk of cardiovascular disease for movers and stayers in New Zealand: a survival analysis. Int J Public Health. 2017. doi: 10.1007/s00038-017-1011-4.
14. Elder JP, Litrownik AJ, Slymen D.J. et al. Tobacco and alcohol use-prevention program for Hispanic migrant adolescents. Am.J. Prev. Med. 2002;23 (4):269-375.
15. Fernando E, Razak F, Lear SA, Anand SS. Cardiovascular Disease in South Asian Migrants. Can J Cardiol. 2015;31(9):1139-1150. doi: 10.1016/j.cjca.2015.06.008.
16. Fiorini G, Cerri C, Bini S, et al. The burden of chronic noncommunicable diseases in undocumented migrants: a 1-year survey of drugs dispensation by a non-governmental organization in Italy. Public Health. 2016;141:26-31. doi: 10. 1016/j.puhe.2016.08.009.
17. Fuchs-Strizek R, Berger T. Psychocardiology in inpatient rehabilitation. Wien Med Wochenschr. 2017. doi: 10.1007/s10354-017-0606-y.
18. Gnagnarella P, Caini S, Maisonneuve P, Gandini S. Carcinogenicity of High Consumption of Meat and Lung Cancer Risk Among Non-Smokers: A Comprehensive Meta-Analysis. Nutr Cancer. 2017:1-13. doi: 10.1080/01635581.2017. 1374420.
19. Habermann M, Stagge M. Indicators for monitoring the integration of elderly migrants in the municipal infrastructure for elder-care. Bundesgesundheitsblatt Gesundheitsforschung. Gesundheitsschutz. 2015;58 (6):601-608. doi: 10.1007/s00103-015-2142-5.
20. Handlos LN, Petersen JH, Bygbjerg IC, Norredam M. Role of disease and demographic factors as determinants of return migration: A nationwide register-based cohort study. Scand J Public Health. 2017:1403494817731008. doi: 10.1177/1403494817731008.
21. Hengst SMC, Smid GE, Laban CJ. The Effects of Traumatic and Multiple Loss on Psychopathology, Disability, and Quality of Life in Iraqi Asylum Seekers in the Netherlands. J Nerv Ment Dis. 2017. doi: 10.1097/NMD.0000000000000750.
22. Iguacel I, Fernández-Alvira JM, Bammann K, et al. Social vulnerability as a predictor of physical activity and screen time in European children. Int J Public Health. 2017. doi: 10.1007/s00038-017-1048-4.
23. Johns E, Sattar N. Cardiovascular and Mortality Risks in Migrant South Asians with Type 2 Diabetes: Are We Winning the Battle?. Curr Diab Rep. 2017;17(10):100. doi: 10.1007/s11892-017-0929-5.
24. Laban CJ, Gernaat HB, Komproe IH, van der Tweel I, De Jong JT. Postmigration living problems and common psychiatric disorders in Iraqi asylum seekers in the Netherlands. J Nerv Ment Dis. 2005;193(12):825-832.
25. Lazo-Porras M, Bernabe-Ortiz A, Málaga G, et al. Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis. 2016;246:36-43. doi: 10.1016/j.atherosclerosis.2015.12.039.
26. Liang XY, Qu YL, Qu KY, Jin CG. Type 2 diabetes prevalence and its risk factors among migrants and nonmigrants aged 35 years and older in Three Gorge Dam area, China. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46(8):697-702.
27. Martin Y, Collet TH, Bodenmann P, et al. The lower quality of preventive care among forced migrants in a country with universal healthcare coverage. Prev Med. 2014;59:19-24. doi: 10.1016/j.ypmed.2013.11.006.
28. Migration and health: key issues. URL: http://www.who.int/migrants/en/.
29. Montesi L, Caletti MT, Marchesini G. Diabetes in migrants and ethnic minorities in a changing World. World J Diabetes. 2016;7 (3):34-44. doi: 10.4239/wjd.v7.i3.34.
30. Müller-Riemenschneider F, Damm K, Meinhard C, et al. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess. 2009;5:Doc16. doi: 10.3205/hta000078.
31. Nørredam M. Migration and health: exploring the role of migrant status through register-based studies. Dan Med J. 2015;62(4):B5068.
32. Ott JJ, Paltiel AM, Becher H. Noncommunicable disease mortality and life expectancy in immigrants to Israel from the former Soviet Union: country of origin compared with host country. Bull World Health Organ. 2009;87(1):20-29.
33. Paszat L, Sutradhar R, Liu Y, et al. Risk of colorectal cancer among immigrants to Ontario, Canada. BMC Gastroenterol. 2017;17(1):85. doi: 10.1186/s12876-017-0642-.
34. Rasmussen T, Yap SE, Stray-Pedersen B, et al. Associated type 1 diabetes risk in children of Pakistani migrants to Norway. Med Hypotheses. 2014;83 (6):664-667. doi: 10.1016/j.mehy.2014.09.013.
35. Rostami H, Samadi M, Yuzbashian E, et al. Habitual dietary intake of fatty acids are associated with leptin gene expression in subcutaneous and visceral adipose tissue of patients without diabetes. Prostaglandins Leukot Essent Fatty Acids. 2017;126:49-54. doi: 10.1016/j.plefa.2017.09.010.
36. Schilling T, Rauscher S, Menzel C, et al. Migrants and Refugees in Europe: Challenges, Experiences and Contributions. Visc Med. 2017;33 (4):295-300. doi: 10.1159/000 478763.
37. Sharma P, Dwivedi S. Nutrigenomics and Nutrigenetics: New Insight in Disease Prevention and Cure. Indian J Clin Biochem. 2017;32(4):371-373. doi: 10.1007/s12291-017-0699-5.
38. Sun ZH, Wu ZZ, Dang WM, et al. An investigation of mental health in migrant workers in an enterprise. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2016;34(8):591-595. doi: 10.3760/cma.j.issn.1001-9391.2016.08.008.
39. The WHO Country. Ukraine. URL: http://www.euro.who.int/en/countries/ukraine.
40. The WHO Regional office for Europe. URL: http://www.euro. who.int.
41. van Ommen B, van den Broek T, de Hoogh I, et al. Systems biology of personalized nutrition. Nutr Rev. 2017;75(8):579-599. doi: 10.1093/nutrit/nux029.
42. Whayne TFJr. Ischemic heart disease and the Mediterranean diet. Curr Cardiol Rep. 2014;16(6):491. doi: 10. 1007/s11886-014-0491-6.
43. Winkler V, Holleczek B, Stegmaier C, Becher H. Cancer incidence in ethnic German migrants from the Former Soviet Union in comparison to the host population. Cancer Epidemiol. 2014;38 (1):22-27. doi: 10.1016/j.canep.2013.10.011.
44. Yin X, Wang L, Li Y, et al. Red meat intake among employees of floating population aged 18-59 years old in China, 2012. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35(11):1202-1207.
45. Zhang M, Wang L, Deng Q, et al. Fruit and vegetables intake among the Chinese migrant population aged 18 to 59 years old in 2012. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35(11):1198-1201.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The relationship of the severity of carotid arteries atherosclerosis and modifiable and non-modifiable risk factors, coronary atherosclerosis in patients with coronary artery disease depending on the presence of type 2 diabetes mellitusL.V. Zhuravlyova, N.A. LopinaKharkiv National Medical University |
---|
Keywords: atherosclerosis of carotid arteries, coronary artery atherosclerosis, coronary artery disease, type 2 diabetes mellitus, modifiable risk factors, non-modifiable risk factors.
List of references:
1. Biduchak AS, Shkrobanets ID, Leonets SI. Epidemiolohichni osoblyvosti khvorob systemy krovoobihu v Ukraini i Chernivetskii oblasti. [Epidemiological features of cardiovascular diseases in Ukraine in Chernivetskii region]. Bukovynskyi medychnyi visnyk (Ukr). 2013;17(3):100-103.
2. Dyslipidemii: diahnostyka, profilaktyka ta likuvannia. Metodychni rekomendatsii Asotsiatsii kardiolohiv Ukrainy / Mitchenko OI, Lutai MI [Dislipidemia: diagnosis, prevention and treatment] (Rus). Kyiv; 2011:25.
3. Zhuravlåva LV, Lopina NA. Znachenye karotydno-femoralnoi skorosty rasprostranenyia pulsovoi volny v prohnozyrovanyy aterosklerotycheskoho porazhenyia venechnikh sosudov v zavysymosty ot nalychyia sakharnoho dyabeta 2-ho typa [Value of carotid-femoral pulse wave velocity in prediction of atherosclerotic lesions of the coronary vessels depending on presence of type 2 diabetes mellitus] Ukrainskyi kardiolohichnyi zhurnal (Rus). 2017;1:43-50.
4. Zhuravlåva LV, Lopina NA, Kuznetsov YV, Ermolenko TY, Pechenyn AV, Serheev VH, Volkov DE, Lopin DA. Metodyka yzmerenyia karotydno-femoralnoi, aortalno-femoralnoi skorosty rasprostranenyia pulsovoi volnû s pomoshchiu [Method of carotid-femoral and aorto-femoral pulse wave velocity measurement using rheography] Liky Ukrainy (Rus).2016;10:22-32.
5. Zhuravlåva LV, Lopina NA, Kuznetsov YV, Ermolenko TY, Pechenyn AV, Serheev VH. i dr. Sravnytelnaia otsenka yzmerenyia skorosty rasprostranenyia pulsovoi volnû s pomoshchiu reohrafyy y ultrazvukovoi dopplerohrafyy [Comparative evaluation of the measurement of carotid-femoral pulse wave velocity using rheograph «ReoCom» and Doppler ultrasound] Sertse i sudyny (Rus).2016;4:72-79.
6. Moskalenko VF, Hulchii OP, Holubchykov MV, Liedoshchuk BO, Liekhan VM, Ohniev VA ta in.; Moskalenko VF, editor. Biostatystyka. [Biostatistics]. Ê.: Knyha plius (Ukr); 2009:184.
7. ESC Guidelines on Diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD / Russian journal of Cardiology. 2014;3(107):7-61 (in russ) Doi: 10.15829/1560-4071-2014-3-7-61.
8. Stabilna ishemichna khvoroba sertsia: adaptovana klinichna nastanova, zasnovana na dokazakh. [Stable ischemic heart disease: adapted, evidence based, clinical guidelines] (Ukr). Kyiv: 2016:177.
9. Unified clinical protocol of primary and secondary (specialized) medical care: Stable ischemic heart disease / The order of MoH of Ukraine 02.03.2016 N 152:61.
10. Unified clinical protocol of primary and secondary (specialized) medical care: Diabetes mellitus type 2 (The order of MoH of Ukraine N 1118 21.12.2012):115.
11. Goldfine AB, Phua EJ, Abrahamson MJ. [Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus] Circulation. (Eng).2014;129:2567-2573.
12. Huang Y., Cai X., Chen P., Mai W. et al. [Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis] Annals of Medicine. (Eng). 2014; 46:684-692.
13. Naito R, Kasai T. [Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives] World J Cardiology. (Eng). 2015;7(3):119-124.
14. Standards of medical care in diabetes - 2016. American Diabetes Association. Diabetes Care.(Eng). 2016;39(1):1-109.
To download
full version need login
Original language: Russian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The peculiarities of the quercetin therapeutic effects at its long-term administration in the treatment of osteoarthritis patients with high comorbidity, cardiovascular and gastrointestinal risksL.O. Voloshyna1, S.I. Smiyan2, O.I. Doholich11 HSEE of Ukraine «Bukovinian State Medical University», Chernivtsi |
---|
Keywords: osteoarthritis, comorbidity, metabolic disorders, treatment, quercetin.
List of references:
1. Voloshyna LO. Otsinka efektyvnosti zastosuvannia kvertsetynu v kompleksnomu likuvanni khvorykh na osteoartroz z vysokym rivnem komorbidnosti, kardiovaskuliarnoho i hastrointestynalnoho ryzykiv (Ukr). Liky Ukrainy plius. [Ukraine medicines plus] (Ukr). 2017;1:31-36.
2. Holovach YIu. Osteoartryt: fundamentalnye y prykladnye aspekty etiopatoheneza zabolevanyia. Nychto ne stoyt na meste. (Ukr). Ukr revmatol zhurn. [Ukr revmatol J] (Ukr). 2014;2;56:4-11.
3. Kovalenko VM. Kalkuliator kardiovaskuliarnoho ryzyku. (Ukr). Zdorovia Ukrainy. [Ukraine health] (Ukr). 2010;3:6.
4. Kovalenko VM. Komorbidnist i shliakhy ratsionalnoi farmakoterapii v revmatolohii.(Ukr). Ukr revmatol zhurn [Ukr revmatol J] (Ukr). 2014;2:12-13.
5. Kupko N. Kvertsetyn: svoistva y prymenenye. (Ukr). Ratsyonalnaia farmakoterapyia. [Rational pharmacotherapy] (Ukr). 2011;4;21:57-60.
6. Mahalias VM, Mikheiev AO, Rohovyi YuI, ta in. Suchasni metodyky eksperymentalnykh i klinichnykh doslidzhen Tsentralnoi naukovo-doslidnoi laboratorii Bukovynskoi derzhavnoi medychnoi akademiii. Navch.-metod. posibnyk (Ukr). Chernivtsi, [Textbook] (Ukr). 2001:42.
7. Mendel OY, Naumov AV, Vertkyn AL, ³ dr. Osteoartroz y serdechno-sosudystye zabolevanyia u lyts pozhyloho vozrasta: klynycheskye y patohenetycheskye vzaymosviazy (Ukr). Uspekhy herontolohyy. [The successes of gerontology] (Ukr). 2010;23;2:304-313.
8. Natsionalnyi pidruchnyk z revmatolohii / Za red. V.M. Kovalenka, N.M. Shuby). (Ukr). Kyiv: Morion, 2013:672s.
9. Parkhomenko OM, Kozhukhov SN, Irkin OI, Lutai YaM. Novi mozhlyvosti farmakolohichnoho vplyvu na prohnoz u khvorykh na infarkt miokarda z elevatsiieiu sehmenta ST ta hostroiu sertsevoiu nedostatnistiu. Korvityn dlia iniektsii. (Ukr). Ukr med chasopys. [Ukr med Chasopys] (Ukr). 2004;2:33-37.
10. Tyts N. Åntsyklopedyia klynycheskykh laboratornûkh testov. Per. s anhl. Pod red. V.V. Menshykova (Eng) Labynform - 1997:960.
11. Fadieienko HD, Hridniev OIe, Nesen AO, ta in. Komorbidnist i vysokyi kardiovaskuliarnyi ryzyk - kliuchovi pytannia suchasnoi medytsyny. (Ukr). Ukr terapevt zhurn. [Ukr therapist J] (Ukr). 2013;1:102-107.
12. Fadieienko HD, Nesen AO. Komorbidnist ta intehratyvna rol terapii vnutrishnikh orhaniv. (Ukr). Ukr terapevt zhurn. [Ukr therapist J] (Ukr). 2015;2:7-15.
13. Iatsyshyn RI, Sukhorebska MIa. Rol biomarkeriv poshkodzhennia suhlobovoho khriashcha u diahnostytsi y otsintsi efektyvnosti likuvannia khvorykh na osteoartroz. (Ukr). Ukr revmatol zhurn. [Ukr revmatol J] (Ukr). 2015;2:36-41.
14. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!) (Eng). Osteoarthritis cartilage. 2013;21:16-21.
15. Bischot SC. Quercetin: potential in the prevention and therapy of disease (Eng). Curr Opin Clin Nutr Metab Care. 2008;11;6:733-740.
16. Chen C, Zhou JJ. Quercetin: a potential drug to reverse multidrug resistance. (Eng). [Life science]. (Eng). 2010;87:333-338.
17. Findlay D.M. Vascular pathology and osteoarthritis. Review (Eng). Rheumatology. 2007;46:1763-1768.
18. Leixuri Aguirre, Noemi Arias, Teresa Macarulla, et al. Beneficial offects of guercetin on obesity and diabetes (Eng). The Open Nutriceuticals J. 2011;4:189-198.
19. Marengoni A, Angleman S, Fratiglioni L. Prevalence of disability acording to multimorbidity and disease clustering: a population-based study. (Eng). J Comorbidity. 2011;1;1:11-18.
20. Parkhomenko A, Kozhukhov S, Gurjeva O. Clinical efficacy of intravenous lipoxygenase inhibitor quercetin in patients with a cube ST-segment elevation myocardial infarction: results of a prospective randomized open-label trial (Eng). Seminars in Cardiology (Eng). 2005;11;4:154-158.
21. Safford MM, Allison II, Kiefe C.I. Patient complexity: more than comorbidity, the vector model of complexity (Eng). J Gen Int Med. 2007;22;3:382-390.
22. Uhlig K, Left B, Kent D, et al. A Framework for crafting clinical practice guidelines that are relevant to the care and management of people with comorbidity. (Eng) J Gen ²nt Med. 2014;29;4:11-18.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 Effects of the complex treatment on indexes of T- and B-cell immunity in patients with nonalcoholic steatohepatitis combined with obesity and pathology of the biliary tractÎ.Yu. FilippovaSE «Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine», Dnipro |
---|
Keywords: non-alcoholic steatohepatitis, obesity, biliary tract, T-lymphocytes, B-lymphocytes, ursodeoxycholic acid, arginine glutamate.
List of references:
2. Balan UV. Indicators of lipid peroxidation, endotoxin, cytokine profile and level of microelements in blood of patients with chronic acalculous cholecystitis under the influence of treatment glutarginom, ursoholom and roksilidom (Ukr). Klinichna meditsina [Clinical medicine] (Ukr). 2009;1(13):18-22.
3. Bokova TA, Ursova NI. Pathology of the hepatobiliary system in children and teenager with obesity and metabolic syndrome (Rus). Vrach [The doctor] (Rus). 2011;1:56-58.
4. Virstyuk NG, Cherkashina OE. Glutargina influence on the functional state of liver in patients with chronic heart failure (Ukr). Galitskiy l³kar visnik [Galician medical journal] (Ukr). 2015;22:4(2):21-23.
5. Drapkyna OM, Popova YP. The role of obesity in the development of hypertension and non-alcoholic fatty liver disease (Ukr). Ukrainskyi medychnyi chasopys [Ukrainian Medical Journal] (Ukr). 2013;2:125-128.
6. Zhuravleva LV, Krivonosova EM, Lopina NA. The use of ursodeoxycholic acid in internal medicine (Ukr). Praktikuyuchiy likar [Practicing doctor] (Ukr). 2014;4:25-32.
7. Yvashkyn VT. The immune system and liver damage in chronic hepatitis B and C (Rus). Ros zhurn hastroenterol hepatol koloproktol. [Russian Journal of Gastroenterology, Hepatology, Coloproctology] (Rus). 2009;6:4-10.
8. Lefkovyts Y, Pernys B. Immunologiya. metody issledovaniy [Immunology. Research methods] (Rus). Moscow: Myr; 1983:188-212.
10. Sochner AM, Belchenko YE, Burshtein AM. Limfozitatoxic test as a method of identifying subpopulations of T-lymphocytes with monoclonal antibodies (Rus). Lab delo [Laboratory work] (Rus). 1989;3:29-32.
9. Petrov RV, Khaytov RM, Pynehyn VV. The immune status of the person in mass surveys: methodological recommendations for researchers and physicians healthcare practice (Rus). Ymmunolohyia [Immunology] (Rus). 1992;6:51-63.
1. Babak OYa, Fadeenko GD, Frolov VM, Kruglova OV. Pathogenetic rationale for the use of metabolically active agents L-arginine-L-glutamate when nonalcoholic fatty liver disease, associated with chronic acalculous cholecystitis (Ukr). Liki Ukrayini [Medicines of Ukraine] (Ukr). 2013;2(168):29-33.
11. Stepanov YuM, Filippova OYu. The features of the changes of T- and B-cell immunity, depending on the body mass index in the patients with the nonalcoholic fatty liver disease in combination with the obesity and the pathology of biliary tract (Ukr). Ukrayinskiy terapevtichniy zhurnal [Ukrainian Therapeutic Journal] (Ukr). 2016;4:46-54.
12. Cherkashina OE. Changes in the functional state of the liver in hypertensive patients complicated by chronic cardiac insufficiency on the background of nonalcoholic steatohepatitis: avtoreferat dis. kand. med. nauk: 14.01.02 - vnutrishni hvorobi. Ivano-FrankIv. nats. med. un-t MOZ Ukrayini. - Ivano-Frankivsk (Ukr). 2016:20.
13. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterol. 2012;142:711-725.
14. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637-653.
15. Sydorchuk A, Boychuk T, Sydorchuk R, Sydorchuk L. Immune and metabolic disorders in obese patients with hepatic steatosis and hypertension associate with PPAR-GAMMA2 PRO12ALA and ACE I/D genes’ polymorphisms. United Eur Gastroenterol J. 2015;1:59.
16. Toouli J, Fried M, Ghafoor KA. Obesity World Gastroenterology Organisation Global Guideline. 2009:30.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The efficiency of prokinetic use in the treatment of gastroesophageal reflux disease with concomitant bronchial asthmaÎ.A. Oparin, A.G. Oparin, G.G. AkhvledianiKhark³v Medical Academy of Postgraduate Education |
---|
Keywords: bronchial asthma, gastroesophageal reflux disease, interleukins, domperidone, comorbidity.
List of references:
1. Arutyunov AG, Burkov SG, Shcherba EP. Mechanisms of interrelation between gastroesophageal reflux disease and bronchial asthma and management tactics. Klinicheskie perspektivy gastroenterologii, gepatologii. 2004;2:5-9. (Rus.).
2. Burkov SG, Arutnov AG, Atabekova LA i dr. Gastroesophageal reflux disease and bronchial asthma. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. Prilozhenie 17. Materialy VIII rossiiskoi gastroenterologicheskoi nedeli. 2002;5:5.(Rus.).
3. Maev IV, Lyamina SV, Kalish SV. Functional activity of alveolar macrophages in patients with bronchial asthma and gastroesophageal reflux disease. Klin Meditsina. 2013;6:41-47. (Rus.).
4. Maev IV, Lyamina SV, Malysheva EV, i dr. The immune response and phenotype of alveolar macrophages in bronchial asthma, gastroesophageal reflux disease and their combinations. Terapevticheskii arkhiv. 2015;3:34-41. (Rus.).
5. Oparin AG, Oparin AA, Titkova AV. Place and role of immunoinflammatory processes in the mechanisms of the formation of chronic obstructive pulmonary disease with combined gastroesophageal reflux disease, taking into account the quality of life of patients. Ukra¿ns’kii terapevtichnii zhurnal. 2013; 3:52-58. (Rus.).
6. Paleev NR, Isakov VA, Ivanova OV. Bronchial asthma and gastroesophageal reflux disease: does the relationship is accidental?. Klinicheskaya meditsina. 2005;1:9-13. (Rus.).
7. Pikulev DV, Alekseeva OP, Dolbin IV. Coronary heart disease and gastroesophageal reflux disease: features of the combined course. Meditsinskii al’manakh. 2012;1:43-47. (Rus.).
8. Fadeenko GD, Gridnev AE. Gastroezofageal’naya reflyuksnaya bolezn’: pishchevodnye, vnepishchevodnye proyavleniya i komorbidnost’. Pod red. A.N. Belovola; 2014:376. (Rus.).
9. Joppa P, Petrasova D, Stencak B, et al. Systemic information in patients with COPD and pulmonary hypertension. Chest. 2009;130:326-333.
11. Laine L, Hennekens C. Proton pump inhibitor and clopidogrelinteraction: fact or ction? Am J Gastroenterol. 2010;105:34-41.
12. Modanic RD. Proton pump inhibitor side effects and drug intractions: much ado about nothing? Cleveland Clin J Med. 2011;78:39-49.
13. Thomas AD, Su KJ, Chang JC, et al. Gastroesophagal reflux-associated aspiration alerts the immune response in asthma. Surg Endoscony. 2010;24(5):1066-1070.
To download
full version need login
Original language: Russian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The prevalence of metabolic syndrome among inpatients of therapeutic department with essential hypertensionN.P. Masik, K.Ya. KalandeyNational Pirogov Memorial Medical University, Vinnytsya |
---|
Keywords: hypertension, metabolic syndrome, obesity, insulin resistance, hyperlipidemia.
List of references:
1. Aleksandrov OV, Alekhina PM, Grigor SP. i dr. Metabolicheskii sindrom. Rossiiskii meditsinskii zhurnal (Rus). 2006;6:50-55.
2. Handziuk VA. Analiz zakhvoriuvanosti na ishemichnu khvorobu sertsia v Ukraini. Ukrainskyi kardiolohichnyi zhurnal (Ukr). 2014;3:45-52.
3. Hidzynska IM, Moroz HZ, Lasytsia TS, Bezuhla MV. Metabolichnyi syndrom ta sertsevo-sudynnyi ryzyk: suchasnyi pohliad na problemu. Arterialna hipertenziia (Ukr). 2012;2:22.
4. Horbas IM. Shkala SCORE v klinichnii praktytsi: perevahy ta obmezhennia. Arterialna hipertenziia (Ukr). 2009;2:4.
5. Diahnostyka metabolichnoho syndromu, tsukrovoho diabetu, prediabetu ta sertsevo-sudynnykh zakhvoriuvan Ukrainskoi asotsiatsii kardiolohiv i Ukrainskoi asotsiatsii endokrynolohiv / uporiad. OI Mitchenko ta in. (Ukr). K, 2009:40.
6. Kovalenko VM, Talaieva TV, Kozliuk AS. Metabolichnyi syndrom: mekhanizmy rozvytku, znachennia yak faktora sertsevo-sudynnoho ryzyku, pryntsypy diahnostyky ta likuvannia. Ukrainskyi kardiolohichnyi zhurnal (Ukr). 2013;5:80-87.
7. Kovalova OM, Ambrosova TN, Vinogradova SV. Metabolicheskii sindrom: problemy diagnostiki i prognosticheskie kriterii. Vnutrennyaya meditsina (Rus). 2008;1:7.
8. Kostina VM, Ziuzin VO, Zinchenko TM. Metabolichnyi syndrom: metody diahnostyky ta reabilitatsii. Naukovi pratsi. Chornomorskoho derzhavnoho universytetu imeni Petra Mohyly kompleksu «Kyievo-Mohylianska akademiia». Seriia: Ekolohiia (Ukr). 2011;152(140):76-78.
9. Kryvenko VI, Fedorova OP, Pakhomova SP, Kolesnyk MYu, Nepriadkina IV, Kachan IS. Osnovni syndromy, poviazani z metabolichnymy porushenniamy, u praktytsi likaria zahalnoi praktyky: navch. posib. Zaporizhzhia (Ukr). ZDMU, 2016:98.
10. Mamedov MN, Oganov RG. Neobkhodimo li opredelenie insulinorezistentnosti dlya diagnostiki metabolicheskogo sindroma v klinicheskoi praktike? Kardiologiya (Rus). 2005;4:92-97.
11. Mitchenko EI. Metabolicheskii sindrom: sostoyanie problemy i lechebnye podkhody. Medichnii portal — Zdorov’ya Ukra¿ni (Rus). 2015. Rezhim dostupa: http://health-ua.com/articles/1216.
12. Pankiv VI. Insulinorezystentnist yak kliuchovyi patofiziolohichnyi mekhanizm rozvytku metabolichnoho syndromu. Praktychna anhiolohiia (Ukr). 2012;5-6:54-55.
13. Rutovskyi YaA, Kachmarska MO. Metabolichnyi syndrom, tsukrovyi diabet: epidemiolohiia i naslidky dlia zdorovia. Ukraina. Zdorovia natsii (Ukr). 2012;2-3:163-167.
14. Svintsitskyi AS, Kozak NP, Ostafiichuk AS. Osoblyvosti perebihu podahry na foni metabolichnoho syndromu. Ukrainskyi revmatolohichnyi zhurnal (Ukr). 2011. Rezhym dostupu: http://www.rheumatology.kiev.ua/wp/wp-content/uploads/2011/12/713.pdf?upload.
15. Shilov AM, Chubarov MV, Melnik MV, Rybkina TE. Arterial’naya gipertenziya i metabolicheskii sindrom Kh. RMZh (Rus). 2003;21:1145.
16. Kaur JA Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice. 2014;2014:21.
17. Perk J, Backer GD. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635-1701.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The genderrelated aspects of changes in the life of quality indices depending on the arterial hypertension degreeÎ. Î. AliferO. O. Bogomolets National Medical University, Kyiv |
---|
Keywords: arterial hypertension, quality of life, gender aspect, SF-36 questionnaire.
List of references:
1. Adherencetolong-termtherapies: Evidence for action. Geneva, WHO, 2003:198.
2. Asadujjaman M, Mishuk AU, Hossain MA, et al. Medicinal potential of Passiflora foetida L. plant extracts: biological and pharmacological activities. J Integr Med. 2014;12(2):121-126.
30. Bardage C, Isacson D. Hypertension and health related quality of life: an epidemiological study in Sweden. J Clin Epidemiol. 2001;54:172-181.
4. Barnason S, Zimmermann L, Anderson A, et al. Functional status outcomes of patients with a coronary artery by pass graft over time. Heart Lung. 2000;29:33-46.
5. Baroletti S, Dell’Orfano H. Medication Adherence in cardiovascular disease. Circulation. 2010. 121:1455-1458.
6. Battersby C, Hartley K, Fletcher A, et al. Quality of the life in treated hypertension: a cause-control community based study. J Hum Hypertens. 1995;9:981-986.
7. Bernatoniene J, Kopustinskiene DM, Jakstas V, et al. The effect of Leonurus cardiaca herb extract and some of its flavonoids on mitochondrial oxidative phosphorylation in the heart. Planta Med. 2014;80(7):525-532.
8. Dalfó A Baqué, Badia X Llach, Roca A-Cusachs Coll, et al. Validation of the quality of life questionnaire in arterial hypertension (HQALY) for its use in Spain. Relationship between clinical variables and quality of life. Investigator Group of the HQALY study. Aten Primaria. 2000;26(2):96-103.
9. Deeks A, Lombard C, Michelmore J, Teede H. The efects of gender and ageon health related behaviors. BMC Public Health. 2009;9:213.
10. Gee M.E, Bienek A, McAlister F.A, et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol. 2012;28(3):375-382.
11. Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am J Hypertens. 2008;21(7):789-798.
12. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213-221.
13. Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31:1281-1357.
14. Hadley S. Valerian, Petry JJ. Am Fam Physician. 2003;67;8:1755-1758.
15. Mancia G, Fagard R, Narkiewicz K, et al. ESH / ESC Guidelines for the management of arterial hypertension. Eur Heart Jour. 2013;34:2159-2219.
16. Noguchi Shinohara M, Ono K, Hamaguchi T, et al. Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One. 2015;10(5):e0126422.
17. Ooi HHL, Coleman PL, Duggan J, O’Meara YM. Treatment of hypertension in the elderly. Current Opinion in Nephrology and Hypertension. 1997;6(5):504-509.
18. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, andcontrol in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007;55:1056-1065.
19. Roca-Cusachs A, Ametlla J, Calero S, et al. Quality of life in arterial hypertension. Med Clin (Barc). 1992;98:486-490.
20. Roca-Cusachs A, Dalfo A, Badia X, et al. Relation between clini-cal and therapeutic variables and quality of life in hypertension. J Hypertens. 2001;19:1913-1919.
21. Sang Hui Chu, Ji Won Baek, Eun Sook Kimetal. Gender Differences in Hypertension Control Among Older Korean Adults: Korean Social Life, Health, and Aging Project. J Prev Med Public Health. 2015;48:38-47.
22. Schulz RB, Rossignoli P, Correr CJ, et al. Validation of the short form of the Spanish hypertension quality of life questionnaire (MINICHAL) for Portuguese (Brazil). Arq Bras Cardiol. 2008;90(2):127-131.
23. Stokes GS. Management of hypertension in the elderly patients. Clin Interv Aging. 2009;4:379-389.
24. Treat-Jacobson D, Lindquist RA, Witt DR, et al. The PADQOL: development and validation of a PAD-specific quality of life questionnaire. Vasc Med. 2012;17(6):405-415.
25. Zamorano J, Rodriguez P, Cosín J, et al. Amlodipine reduces predicted risk of coronary heart disease in high-risk patients with hypertension in Spain (The CORONARIA Study). J Int Med Res. 2008;36(6):1399-1417.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 Use of platelet autologous plasma in the treatment of post-traumatic knee osteoarthritisL.V. Khimion, G.O. HavryliukP.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv |
---|
Keywords: post-traumatic osteoarthritis, platelet autologous plasma, treatment.
List of references:
1. Davydkina IL, Shchukina YuV. Poliklinichna terapiia / Pid red. IL Davydkinoi. M: HEOTAR-Mediia, 2013:688.
2. Kovalenko VN, Bortkevych OP. Osteoartroz. K.: Moryon; 2003:448.
3. Nasonova VA. Osteoartroz kolennoho sustava: prychynû razvytyia, dyahnostyka, profylaktyka. Consilium medicum. 2003;5(2):90-95.
4. Anitua E, Sanchez M, Zalduendo MM, et al. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009;42:162.
5. Brown TD, Johnston RC, Saltzman CL, et al. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma. 2006;20(10):739-744.
6. Cerza F, Carni S, Carcangiu A. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Sports Med. 2012;40:822-827.
7. Cross. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Annals of the rheumatic diseases. 2014;73:1323-1330.
8. Drengk A, Zapf A, Sturmer EK, et al. Influence of platelet-rich plasma on chondrogenic differentiation and proliferation of chondrocytes and mesenchymal stem cells. Cells Tissues Organs. 2009;189:317.
9. Frobell RB, Roos HP, Roos EM, et al. Treatment for acute anterior cruciate ligament tear: five year outcome of randomised trial. BMJ. 2013;346:f232.
10. Gelber AC, Hochberg MC, Mead LA, et al. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133(5):321-328.
11. Haynes S, Gemmell H. Topical treatments for osteoarthritis of the knee. Clin Chiropractic. 2007;10(3):126-138.
12. Kieswetter K, Schwartz Z, Alderete M, et al. Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation. Endocrine 1997;6:257.
13. Kon E, Buda R, Filardo G. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy. 2011;27:1490-1501.
14. Kon E, Buda R, Filardo G. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc. 2010;18(4):472-479.
15. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
16. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35(10):1756-1769.
17. Lohmander LS, Ostenberg A, Englund M, Roos H. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum. 2004;50(10):3145-3152.
18. Lotz M. Cytokines in cartilage injury and repair. Clin Orthop Relat. 2001;391:108-115.
19. Lotz M. New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther. 2010;12(3):211.
20. Otsuki S, Brinson DC, Creighton L, et al. The effect of glycosaminoglycan loss on chondrocyte viability: a study on porcine cartilage explants. Arthritis Rheum. 2008;58:1076-1085.
21. Petrera M, De Croos JN, Iu J, et al. Supplementation with platelet-rich plasma improves the in vitro formation of tissue-engineered cartilage with enhanced mechanical properties. Arthroscopy. 2013;29:1685.
22. Riegger J, Joos H, Palm HG, et al. Antioxidative therapy in an ex vivo human cartilage trauma-model: attenuation of trauma-induced cell loss and ECM-destructive enzymes by N-acetyl cysteine. Osteoarthritis Cartilage. 2016;24(12):2171-2180.
23. Roos H, Lauren M, Adalberth T, et al. Knee osteoarthritis after meniscectomy: prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum. 1998;41(4):687-693.
24. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008;1(3-4):165-174.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 The combination of gastroesophageal reflux disease with coronary heart disease: a non-invasive method of diagnosisG.D. Fadeenko, À.Î. Nesen, Î.Î. Krakhmalova, O.V. IzmailovaSI «National Institute of Therapy named after L.T. Mala of the NAMS of Ukraine», Kharkiv |
---|
Keywords: gastroesophageal reflux disease, coronary heart disease, comorbidity, sleep disorders, obstructive sleep apnea/hypopnea syndrome, melatonin.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 Dyslipidemia in oncopathology: is it a risk factor or a consequence of cancerogenesis?V.A. ChernyshovSI «National Institute of Therapy named after L.T. Mala of NAMS of Ukraine», Kharkiv |
---|
Keywords: lipids, lipoproteins, oncopathology.
List of references:
1. Abdelsalam KE, Hassan IK, Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci. 2012;17:562-565.
2. Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem. 2011;54:5615-5638.
3. Baenke F, Peek B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumor development. Disease Models and Mechanisms. 2013;6:1353-1363.
4. Bhat SA, Mir MR, Majid S, et al. Serum lipid profile of breast cancer patients in Kashmir. J Invest Biochem. 2013;2:26-31.
5. Bjorge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010;19:1737-1745.
6. Cruz P, Torres C, Kamirez ML et al. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1(3):531-536.
7. Dabrowa AB, Hannam S, Rysz J, Banach M. Malignancy — associated dyslipidemia. Open Cardiovasc Med J. 2011;5:35-40.
8. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333:233-238.
9. Freeman MR, Di Vizio D, Solomon KR. The rafts of the medusa: cholesterol targeting in cancer therapy. Oncogene. 2010;29:3745-3747.
10. Fujimoto M, Higuchi T, Hosomi K, Takeda M. Association between statin use and cancer: data mining of spontaneous reporting database and a claims database. Int J Med Sci. 2015;12:223-233.
11. Hegele RA. Plasma lipoproteins: genetic influence and clinical implications Nat Rev Genet. 2009;10:109-121.
12. Hilvo M, Denkert C, Lehtinen L, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011;71:3226-3245.
13. Holzmann MJ, Jungner I, Walldius G, et al. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med. 2012;44:262-270.
14. Hsu PP, Sabatini DM. Cancer cell metabolism. Warburg and beyond Cell. 2008;134:703-707.
15. Jawalekar S. The hyperlipoproteinemia - an approach to diagnosis and classification. Biochem Physiol. 2012;1:e105.
16. Jerby L, Wolf L, Denkert C, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 2012;72:5712-5720.
17. Kikuchi H, Nanri A, Hori A. Lower serum levels of total cholesterol are associated with higher urinary levels of 8-hydroxydeoxyguanosine. Nutrition and Metabolism. 2013;10:59.
18. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592-1598.
19. Klopp AH, Zhang Y, Solley T, et al. Omental adipose tissue-derived stromal cell promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012;18:771-782.
20. Kumar P, Augustine J, Urs AB, et al. Serum lipid profile in oral cancer and leukoplakia: correlation with tobacco abuse and histological grading. J Cancer Res Ther. 2012;8:384-388.
21. Kushiba A, Monkawa T, Yamauchi M, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses health study. J Natl Cancer Inst. 2012;104:415-420.
22. Laisupasin P, Thompat W, Sukarayodhin S, et al. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Phys. 2013;5:38-41.
23. Lui YL, Qian HX, Qin L, et al. Association of serum lipid profile with distant metastasis in breast cancer patients. Chinese Journal of Oncology. 2012;34:129-131.
24. Melvin JC, Seth D, Holmberg L, et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev. 2012;21:1381-1384.
25. Moradian AD/ Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metabol. 2009;5:150-159.
26. Murtola TJ, Syvala Y, Pennanen P, et al. The importance of LDL and cholesterol metabolism for prostate epithelial cell growth. Plos One;7:e39455.
27. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide enegy for rapid tumor growth. Nat Med. 2011;17:1496-1503.
29. Peela JR. The relationship between serum lipids and breast cancer in Libya. Biochem Anal Biochem. 2012;1:1-3.
30. Radisauskas R, Kuzmickiene I, Milinaviciene E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina. 2016;52:89-98.
31. Rysman E, Brusselmans K, Scheys K, et al. De novo lipogenesis protects cancer cell from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70:8117-8126.
32. Santos CR, Schultze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610-2623.
33. Strohmaier S, Edlinger M, Manjer J, et al. Total serum holesterol and cancer incidence in the metabolic syndrome and cancer Project (Me-Can). Plos One. 2013;8:e54242.
34. Tamura T, Inagawa S, Hisakura K, et al. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol. 2012;27:1635-1640.
35. Tumovska Y, Pivnyuk V, Todor I, et al. The spectrum of blood serum lipids in patients with breast cancer without metabolic syndrome. Exp Oncol. 2011;33:190-192.
36. Wakabayashi I. Relationship between alcohol intake and atherogenic indices in women. J Clin Lipidol. 2013;7:454-462.
37. Yang MH, Rampal S, Sung J, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol. 2013;108:833-841.
38. Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. Can Med Assoc J. 2008;179:427-437.
39. Zaidi N, Lupten L, Kuemerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52:585-589.
40. Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3(8):167-174.
To download
full version need login
Original language: Russian
|
Notice: Undefined index: pict in /home/vitapol/utj.vitapol.com.ua/en/svizhij_nomer.php on line 75 Endothelial dysfunction and its role in the pathogenesis of chronic obstructive pulmonary disease. Part II²O.I. Lemko, N.V. VantyukhGI «The Scientific-practical Medical Center “Rehabilitation” of the Ministry of Health of Ukraine», Uzhhorod |
---|
Keywords: chronic obstructive pulmonary disease, endothelial dysfunction, immune disorders, apoptosis, hemostasis, genetic factors.
List of references:
1. Abrosimov VN. Bronchial asthma, wheezing, flatter: probable relationships (Rus). Russian Pulmonology (Rus). 2016;26 (6):719-724.
2. Bychkova NG, Bychkova SA. Immune status of patients with chronic obstructive pulmonary disease, accompanied with chronic kidney disease and metabolic disturbances (Ukr). Ukr J of nephrology and dialises (Ukr). 2015;1:8-13.
3. Gabor ML, Lemko OI. Antioxidant defense, lipids’ peroxidation and cytokine status at patients with chronic obstructive pulmonary disease (Ukr). Ukr Med Almanach (Ukr). 2010;13(3):40-42.
4. Zhelezniakova NM. Immunological aspects of comorbid course of chronic obstructive pulmonary disease and chronic pancreatitis (Ukr). Ukr Therapeut J (Ukr). 2014;2:80-84.
5. Krakhmalova EO, Hetman EA. Assessment of the impact of pulmonary hypertension syndrome on the clinical features and platelet hemostasis in patients with COPD and concomitant coronary artery disease (Rus). Ukr Therapeut J (Ukr). 2013;3:26-32.
6. Krakhmalova EO, Hetman EA. Syndrome of pulmonary hypertension at the comorbidity of chronic obstructive pulmonary disease and coronary heart disease (Rus). Ukr Therapeut J (Ukr). 2017;1:81-88.
7. Lemko IS, Kazankevich VP, Lemko OI et al. The dynamics of immunological data at patients with chronic obstructive bronchitis under the influence of rock-salt microclimatotherapy (Ukr). Scientific Bulletin of Uzhgorod University. Medical Series (Ukr). 2003;13:126-133.
8. Lemko OI, Vantyukh NV, Reshetar DV. Characteristic of some humoral immunity indices in patients with chronic obstructive pulmonary disease (Ukr). Actual questions of balneology, physiotherapy, and medical rehabilitation (Rus). 2009;20(2):133-140.
9. Lemko OI, Gabor ML, Bolohovska VA, Vantyukh NV. The possibility of lactic acid bacteria’s peptidoglycanes usage in immunorehabilitation at patients with chronic obstructive pulmonary disease (Ukr). Clin Immunol Allergol Infectol (Ukr). 2012;3:88-93.
10. Lemko OI, Gabor ML, Lemko IS, Reshetar DV. Some indices of the mucosal local defense and inflammatory activity at patients with chronic obstructive pulmonary disease (Ukr). Asthma and Allergy (Ukr). 2009;1-2:55-59.
11. Lemko OI, Vantyukh NV, Popadinets MI. The expression of apoptosis’ markers on lymphocytes and neutrophylls in patients with chronic obstructive pulmonary disease (Ukr). Asthma and Allergy (Ukr). 2010;1-2:18-20.
12. Lemko OI, Reshetar DV. Peculiarities of the cytokine status and inflammatory activity in patients with chronic obstructive pulmonary disease (Ukr). Àsthma and Allergy (Ukr). 2012;3:12-17.
13. Makarova MA, Avdeev SN, Chuchalin AG. The role of endothelial dysfunction and arterial rigidity in pathogenesis of chronic obstructive pulmonary disease (Rus). Therapeut Arch (Rus). 2012;3:74-80.
14. Mamaeva MG, Demko IV, Verigo YI et al. Markers of systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease (Rus). Sybirian Med Reviev (Rus). 2014;1:12-19.
15. Masik NP, Malenkiy VP. The role of systemic inflammation in development of osteopenia in patients with COPD (Ukr). Ukr Pulmonol J (Ukr). 2010;2:36-38.
16. Oparin AG, Oparin AA, Titkova AV. The role and place of immune inflammatory processes in the mechanisms of the development of chronic obstructive pulmonary disease with concomitant gastroesophageal reflux disease taking into account the patients’ quality of life (Rus). Ukr Therapeut J (Ukr). 2013;3:52-56.
17. Pertseva TO, Konopkina LI, Yakovleva VN, Voronina NO. Peculiarities of hemostasis in patients with different phases of pathological process (Ukr). Ukr Pulmonol J (Ukr). 2015;2:52-55.
18. Pertseva TO, Myhailichenko DS. Serum level of transforming growth factor-β1 in patients with chronic obstructive pulmonary disease and its correlation with clinical and functional indices (Rus). Ukr Pulmonol J (Ukr). 2016;4:33-36.
19. Rasputina LV. Markers of systemic inflammation and endothelial dysfunction in patients with combined course of chronic obstructive pulmonary disease and hypertension (Ukr). Asthma and Allergy (Ukr). 2012;2:17-21.
20. Rekalova EM, Panasiukova OR, Chernushenko EF et al. The features of immunological reactivity in patients with chronic obstructive pulmonary disease and concomitant cardiovascular disease (Ukr). Asthma and Allergy (Ukr). 2015;3:40-46.
21. Sedaia LV, Syniachenko IV, Yiermolaieva MV, Bevzenko TB. Endothelial dysfunction of vessels at ANCA-associated systemic vasculitis (Ukr). Zaporozhye Med J (Ukr). 2015;4(91):58-61.
22. Seredyuk VN. Dynamics of apoptosis induction Fas-ligand by using of bistep of renin-angiotensin-aldosterone system in patients with chronic pulmonary heart (Ukr). Ukr Therapeut J (Ukr). 2011;1:24-27.
23. Sobko EA, Kraposhina AYu, Demko IV et al. CD 38/F-rybosyl cyclase as a marker of endothelial dysfunction in asthma (Rus). Klinicheskaya meditsina (Rus). 2013;2:34-38.
24. Titova O.N, Kuzubova N.A, Zolotnitskaya V.P. et al. A role of endothelial dysfunction for development of microcirculation and cardiopulmonary blood flow abnormalities in patients with COPD and different alpha‑1-antitrypsin phenotypes (Rus). Russian Pulmonology (Rus). 2017;27(1):29-36. DOI:10.18093/0869-0189-2017-27-1-29-36.
25. Tseimakh IYa, Momot AP, Kostyuchenko GI et al. Role of endothelial dysfunction, the interface between hemostatic and system inflammatory responses in the pathogenesis of an infectious inflammation-dependent exacerbation of chronic obstructive pulmonary disease (Rus). Ther Arch (Rus). 2013;3:17-22.
26. Chubarova SV, Sobko EA, Demko IV et al. Clinical, functional and laboratory features of asthma — COPD overlap syndrome (Rus). Russ Pulmonol (Rus). 2016;26:649-656.
27. Shmelev YeI, Chmeleva NM. The modern anti-inflammatory therapy at patients with chronic obstructive pulmonary disease (Rus). Ther Arch (Rus). 2012;6:73-76.
28. Yachnyk AI, Svintsitsky AS, Shuper SV. Chronic obstructive pulmonary disease and coronary artery disease: parallels and crossroads of comorbidity (Ukr). Ukr Pulmonol J (Ukr). 2014;4:38-42.
29. Begum A, Venkateshwari FM, Jyothy A. Association of CYPA1 gene polymorphism with plasma nitric oxide levels in COPD. BMC Genomics. 2014;15(2):9. DOI: 10.1186/1471-2164-15-S 2-O9.
30. Brusselle GG, Joos GF, Bracke KK. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378:1015-1026.
31. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-3561.
32. Cho JG, Witting PK, Verma M et al. Tissue vibration induces carotid artery endothelial dysfunction: a mechanism linking snoring and carotid atherosclerosis. Sleep. 2011;1(6):751-757. DOI: 10.5665/SLEEP.1042.
33. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). Global strategy for Asthma Management and Prevention. 2014. Available at: http//www.jinasthma.org
34. Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging. 2003;30(4):615-630.
35. Fu J, McDonald V, Gibson P et al. Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res. 2014;6(4):316-324.
36. Gane J, Stockley R. Mechanisms of neutrophil transmigration across the vascular endothelium in COPD. Thorax. 2012;67(6):553-561. DOI: 10.1136/thoraxjnl‑2011-200088
37. Garcia-Lucio J, Argemi G, Tura-Ceide O et al. Gene expression profile of angiogenic factors in pulmonary arteries in COPD: relationship with vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2016;310(7): L583–L592. DOI: 10.1152/ajplung.00261.2015.
38. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org.
39. Guedes A, Deshpande D, Dileepan M et al. CD 38 and airway hyper-responsiveness: studies on human airway smooth muscle cells and mouse models. J Physiol Pharmacol. 2015;93(2):145-153.
40. Kuzubova NA, Chukhlovin AB, Morozova EB et al. Common intronic D variant of ACE gene is associated with endothelial dysfunction in COPD. Respir Med. 2013;107(8):1217-1221. DOI: 10.1016/j.rmed.2012.12.025.
41. Maclay JD, McAllister DA, Johnston S et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769-774.
42. Olivieri D, Chetta A. Therapeutic perspectives in vascular remodeling in astma and chronic obstructive pulmonary disease. Chem Immunol Allergy. 2014;99:2016-225. DOI:10.1159/000353307.
43. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators of inflammation. 2013. Available at: http://dx.doi.org/10.1155/2013/413735
44. Sabit R, Thomas P, Shale DJ et al. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest. 2010;138:47-51.
45. Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic cor pulmonale in COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):273-282.
46. Vaguliene N, Zemaitis M, Lavinskiene S et al. Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. BMC Immunol. 2013;6: 14-36.
47. Vaidula VP, Criner GJ, Gabianowski C, Rao AL. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res. 2009;124:259-261.
48. Woolhouse IS, Bayley DL, Lalor P et al. Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease. Eur Respir J. 2005;25(4):612-617. DOI: 10.1183/09031936.05.00086304.
49. Yang IV, Coldren CD, Leach SM et al. Expression of cilium-associated genes novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax. 2013;68(12):1114-1121. DOI: 10.1136/thoraxjnl‑2012-202943.
50. Zvezdin B, Milutinov S, Kojicic M et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136(2):376-380. DOI: 10.1378/chest.08-2918.
To download
full version need login
Original language: Ukrainian
¹4(55) // 2017